Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate
- PMID: 3286860
- DOI: 10.1002/jps.2600770318
Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate
Abstract
A specific and reproducible high-performance liquid chromatographic (HPLC) procedure was developed for the quantitative analysis of carboplatin (JM-8) in dog plasma ultrafiltrate. Plasma ultrafiltrate samples were generated using Amicon Centrifree micropartition systems or Amicon Centriflo cones, and injected onto a microBondapak NH2 column. The mobile phase consisted of acetonitrile:methanol:0.005 M sodium perchlorate, pH 2.4 (77-75:13-15:10, v/v/v); the flow rate was 1.5 mL/min. Detection was performed by monitoring UV absorbance of the column effluent at 229 nm. Carboplatin eluted between 9.5 and 11.0 min. The internal standard, JM-10, eluted between 11.0 and 13.0 min. The peak height ratio of carboplatin:internal standard versus carboplatin concentration was linear over a range of 0.2 to 20.0 micrograms/mL. The limit of quantitation was 0.2 microgram/mL. The intra-assay precision of this method, as measured by percent relative standard deviation (%RSD), was within 12% for the theoretical concentrations 0.5, 5.0, and 50.0 micrograms/mL. Accuracies were within 11%. The results of the validation procedures indicated that this procedure was accurate and specific.
Similar articles
-
High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine.Cancer Chemother Pharmacol. 1986;16(3):201-6. doi: 10.1007/BF00293978. Cancer Chemother Pharmacol. 1986. PMID: 3516429
-
In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.Cancer Chemother Pharmacol. 1987;20(4):271-6. doi: 10.1007/BF00262576. Cancer Chemother Pharmacol. 1987. PMID: 3319277
-
High-performance liquid chromatographic assay for carboplatin in ultrafiltered plasma combined with hyperbaric oxygenation.Drug Metab Pharmacokinet. 2006 Oct;21(5):429-31. doi: 10.2133/dmpk.21.429. Drug Metab Pharmacokinet. 2006. PMID: 17072097
-
Validation of high-performance liquid chromatographic assay methods for the analysis of carboplatin in plasma ultrafiltrate.J Chromatogr B Biomed Sci Appl. 2000 Jul 21;744(2):367-76. doi: 10.1016/s0378-4347(00)00262-0. J Chromatogr B Biomed Sci Appl. 2000. PMID: 10993526
-
Simple and rapid determination of carboplatin in plasma by high-performance liquid chromatography. Error pattern and application to clinical pharmacokinetic studies.J Chromatogr B Biomed Sci Appl. 2001 Nov 25;764(1-2):457-64. doi: 10.1016/s0378-4347(01)00320-6. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11817042 Review.
Cited by
-
Clinical pharmacokinetics of carboplatin.Clin Pharmacokinet. 1991 Oct;21(4):242-61. doi: 10.2165/00003088-199121040-00002. Clin Pharmacokinet. 1991. PMID: 1760899 Review.
-
A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates.Cancer Chemother Pharmacol. 1992;30(3):193-8. doi: 10.1007/BF00686311. Cancer Chemother Pharmacol. 1992. PMID: 1628368
-
A limited sampling method for estimation of the carboplatin area under the curve.Cancer Chemother Pharmacol. 1993;31(4):324-7. doi: 10.1007/BF00685679. Cancer Chemother Pharmacol. 1993. PMID: 8422698
-
Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients.Cancer Chemother Pharmacol. 1991;28(5):397-401. doi: 10.1007/BF00685696. Cancer Chemother Pharmacol. 1991. PMID: 1914085
-
Renal handling of carboplatin.Cancer Chemother Pharmacol. 1992;30(4):317-20. doi: 10.1007/BF00686302. Cancer Chemother Pharmacol. 1992. PMID: 1643701
MeSH terms
Substances
LinkOut - more resources
Full Text Sources